The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer.
 
Kristen Simmons
No Relationships to Disclose
 
Bryan K. Kee
Stock and Other Ownership Interests - Medtronic
 
Kanwal Pratap Singh Raghav
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Eisai
Speakers' Bureau - Bayer
Research Funding - Bayer (Inst); Daiichi Sankyo/Lilly (Inst); Guardant Health (Inst); Roche/Genentech (Inst)
 
Benny Johnson
Consulting or Advisory Role - Gritstone Bio; Incyte; Insmed; Taiho Oncology
Research Funding - Bristol-Myers Squibb (Inst); Syntrix Biosystems (Inst)
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; MolecularMatch
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Xilis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Jason Willis
Honoraria - Cor2Ed
 
Arvind Dasari
Consulting or Advisory Role - Crinetics Pharmaceuticals; Hutchison MediPharma; Ipsen; Lexicon; Novartis; Personalis; Voluntis
Research Funding - Eisai; Guardant Health; Hutchison MediPharma; Ipsen; Merck; Novartis
 
Eduardo Vilar Sanchez
Consulting or Advisory Role - Janssen Research & Development; Recursion Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Texas MD Anderson Cancer Center, Vilar E, Chang K, Wu W, Bowen CM, Sinha K. Methods and Compositions Comprising MHC Class I Peptides, United States, 63/171,137, 4/6/2021, Filed (Provisional); The University of Texas MD Anderson Cancer Center, Vilar E, Wu W, Katayama H, Hanash S, Bommi P. Methods for Prognosing, Diagnosing, and Treating Colorectal Cancer, United States, 63/152,751, 2/23/2021, Filed (Provisional)
Travel, Accommodations, Expenses - Janssen Research & Development
 
Kaysia Ludford
No Relationships to Disclose
 
Christine Megerdichian Parseghian
No Relationships to Disclose
 
Michael Sangmin Lee
No Relationships to Disclose
 
Phat Le
No Relationships to Disclose
 
John Paul Y.C. Shen
Stock and Other Ownership Interests - Agios; Mirat; Syndax; Syndax
Consulting or Advisory Role - Engine Biosciences
Research Funding - Celsius Therapeutics; Celsius Therapeutics
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Van K. Morris
Consulting or Advisory Role - Axiom Healthcare Strategies; Bicara Therapeutics; BioMedical Insights; Boehringer Ingelheim; Incyte; SERVIER
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Immatics; Pfizer (Inst)